An approach to predict and inhibit Amyloid Beta dimerization pattern in Alzheimer's disease

Area of Science:

• Neuroscience
• Computational Biology
• Pharmacology

Background:

• Alzheimer's Disease (AD) is a leading neurodegenerative disorder.
• The amyloid hypothesis, focusing on Amyloid Beta (Aβ) plaques, is a prominent theory for AD's cause.
• AD presents as sporadic (later onset) or familial (early onset) forms, with mutations in Amyloid Precursor Protein (APP) linked to familial AD.

Purpose of the Study:

• To differentiate wild-type Aβ dimers in sporadic AD from mutant dimers in familial AD using molecular modeling.
• To investigate the potential of repurposing existing anti-inflammatory drugs for AD treatment by assessing their ability to inhibit Aβ dimer formation.

Main Methods:

• Molecular modeling was employed to analyze and differentiate Aβ dimers.
• Virtual screening and molecular docking simulations were used to evaluate anti-inflammatory drugs for their inhibitory effects on Aβ dimer formation.

Main Results:

• Distinct binding interactions were analyzed for wild-type and mutant Aβ dimers.
• Several anti-inflammatory drugs showed potency in resisting Aβ dimer formation through computational analysis.

Conclusions:

• Molecular modeling provides insights into Aβ dimer differences in AD subtypes.
• Drug repurposing of anti-inflammatory agents presents a novel therapeutic strategy for Alzheimer's Disease, potentially inhibiting amyloid plaque formation.